Table 1 Baseline data
Variables | Dexmedetomidine group (n = 303) | Control group (n = 306) |
|---|---|---|
Age, mean (SD), year | 69.1 (6.6) | 69.0 (6.4) |
BMI, Kg/m2, mean (SD) | 24.1 (3.2) | 24.1 (3.4) |
BMI ≥ 30, n (%) | 12 (4.0) | 12 (3.9) |
Female, n (%) | 179 (59.1) | 186 (60.8) |
Preoperative comorbidity, n (%) | ||
Hypertension | 143 (47.9) | 144 (46.7) |
Coronary artery disease | 43 (14.2) | 49 (16.0) |
Arrhythmia | 24 (7.9) | 30 (9.8) |
Congestive heart failure | 0 (0.0) | 2 (0.7) |
Stroke | 27 (8.9) | 33 (10.8) |
Diabetics | 70 (23.1) | 62 (20.3) |
Hyperlipidemia | 8 (2.6) | 13 (4.2) |
COPD | 4 (1.3) | 5 (1.6) |
ASA classification, n (%) | ||
I | 35 (11.6) | 41 (13.4) |
II | 240 (79.2) | 228 (74.5) |
III | 28 (9.2) | 37 (12.1) |
Baseline blood glucose, mean (SD), mmol/L | 6.0 (1.9) | 5.9 (1.5) |
Baseline blood glucose grade, n (%) | ||
≤ 6.1 mmol/L | 218 (71.9) | 219 (71.6) |
6.1–7.0 mmol/L | 40 (13.2) | 39 (12.7) |
≥ 7.0 mmol/L | 45 (14.9) | 48 (15.7) |
CCI, median (IQR), score a | 4 (4, 5) | 4 (4, 5) |